Search Results

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation (“the Gates Foundation” or “the foundation”).

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announced that it had won an award from the U.S. Defense Innovation Unit, a division of the U.S. Department of Defense, for ‘Exhaled Breath Diagnostics’.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), is pleased to announce a Memorandum of Understanding (“MOU”) between SQI and Owlstone Medical to work together on the discovery, development and commercialization of breath-based biomarkers relating to invasive aspergillus lung infection and lung transplant rejection.